Cannabics Pharmaceuticals Inc is a leading pharmaceutical company that focuses on developing and commercializing personalized cannabinoid medicine. With a commitment to innovation and research, Cannabics Pharmaceuticals Inc aims to improve the lives of patients by harnessing the therapeutic potential of cannabinoids. The company's corporate philosophy revolves around quality, transparency, and patient-centricity, ensuring the highest standards in its products and services. Cannabics Pharmaceuticals Inc strives to provide safe and effective treatment options while promoting overall well-being and advancing the field of cannabinoid-based medicine.

Cannabics Pharmaceuticals Inc is primarily present in the United States, Israel, and Europe. The company focuses on the research, development, and commercialization of cannabinoid-based therapies for various medical conditions. With headquarters in Tel Aviv, Israel, Cannabics Pharmaceuticals Inc operates through its subsidiaries and collaborations in these key regions to expand its global presence and reach patients worldwide. Through its innovative approach to cannabinoid-based medicine, the company aims to provide effective and safe treatment options for patients in countries and regions where medical cannabis is legally permitted.

Cannabics Pharmaceuticals Inc has achieved significant milestones in the cannabis industry. The company has successfully developed and patented a personalized medicine platform, utilizing advanced cannabinoid-based diagnostic tools. They have also conducted extensive clinical trials, demonstrating the potential therapeutic benefits of their cannabis-based formulations in various medical conditions. Cannabics Pharmaceuticals Inc has obtained regulatory approvals, enabling them to distribute their innovative products worldwide. Additionally, the company has established strategic partnerships and collaborations with leading institutions, further advancing their research and development efforts. With their persistent commitment to medical cannabis innovation, Cannabics Pharmaceuticals Inc continues to pave the way for transformative treatment options.

Cannabics Pharmaceuticals Inc is a renowned company specializing in the development of personalized cannabinoid medicines. Founded in 2004, it has made significant contributions to the medical cannabis industry. Cannabics Pharmaceuticals Inc conducts comprehensive research and utilizes cutting-edge technology to create innovative therapies for cancer patients. The company's foundation lies in its commitment to improving patients' lives through the utilization of cannabinoids. With extensive experience in the field, Cannabics Pharmaceuticals Inc has become a leading name in the development of personalized cannabinoid-based treatments, aimed at addressing various symptoms and improving the quality of life for patients worldwide.

The main competitors of Cannabics Pharmaceuticals Inc in the market include pharmaceutical companies focused on developing cannabinoid-based therapies and products. Some prominent competitors in this space are GW Pharmaceuticals, Tilray Inc, and Cronos Group Inc. These companies also operate in the medical cannabis industry and strive to develop innovative treatments and solutions for various medical conditions. As Cannabics Pharmaceuticals Inc continues to expand its product portfolio and research pipeline, it faces competition from these established players in the market.

Cannabics Pharmaceuticals Inc is primarily active in the pharmaceutical and healthcare industries.

The business model of Cannabics Pharmaceuticals Inc. revolves around the development and commercialization of cannabinoid-based therapies and biotechnological tools for personalized cancer treatment. With a focus on precision medicine, the company utilizes proprietary technology to analyze patients' individual cancer profiles and provide tailored treatment options. Cannabics Pharmaceuticals aims to enhance patients' quality of life by leveraging the potential of cannabinoids and advancing medical cannabis research. By continuously expanding its pipeline and partnering with medical institutions, the company strives to revolutionize cancer care through innovative therapies and personalized medicine.

KGV-d ei saa praegu Cannabics Pharmaceuticals jaoks arvutada.

KUV-d ei ole võimalik hetkel Cannabics Pharmaceuticals jaoks arvutada.

AlleAktien kvaliteediskoor ettevõttele Cannabics Pharmaceuticals on 6/10.

Praegu ei saa Cannabics Pharmaceuticals käivet arvutada.

Praegu ei ole võimalik kasumit Cannabics Pharmaceuticals jaoks arvutada.

Cannabics Pharmaceuticals Inc. is a biopharmaceutical company focused on researching, developing, and marketing novel therapies for the treatment of cancer and specific medical conditions. The company utilizes innovative technologies to identify specific cannabinoids that target certain types of cancer or symptoms in order to enhance the effectiveness of therapies. Answer: Cannabics Pharmaceuticals Inc. is a biopharmaceutical company focused on researching, developing, and marketing novel therapies for the treatment of cancer and specific medical conditions.

Cannabics Pharmaceuticals maksab dividendi 0 USD, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu Cannabics Pharmaceuticals jaoks arvutada või ettevõte ei maksa dividende välja.

Cannabics Pharmaceuticals ISIN on US13764M1009.

Cannabics Pharmaceuticals WKN on A116WM.

Cannabics Pharmaceuticals tähis on CNBX.

Viimase 12 kuu jooksul maksis Cannabics Pharmaceuticals dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab Cannabics Pharmaceuticals tõenäoliselt dividendi summas 0 USD.

Cannabics Pharmaceuticals praegune dividenditootlus on .

Cannabics Pharmaceuticals maksab kvartaalset dividendi. See makstakse välja kuudel .

Cannabics Pharmaceuticals maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 USD. See vastab dividenditootlusele 0 %.

Cannabics Pharmaceuticals on liigitatud sektorisse 'Tervis'.

Viimase Cannabics Pharmaceuticals dividendide saamiseks 11.7.2024 suuruses 0 USD pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 11.7.2024.

Viimane dividendimakse toimus 11.7.2024.

Aastal 2023 maksis Cannabics Pharmaceuticals 0 USD dividende.

Cannabics Pharmaceuticals dividendid makstakse välja USD.